Keros Doses First Patient in Phase 2 DMD Trial for Rinvatercept…

Event summary

Keros Therapeutics dosed the first patient in its Phase 2 trial of rinvatercept for Duchenne muscular dystrophy (DMD) on September 28, 2026.
The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in late-ambulatory and early non-ambulatory DMD patients.
Rinvatercept targets myostatin and activin A, negative regulators of muscle and bone mass, aiming to improve muscle regeneration and strength.
Keros is also developing rinvatercept for amyotrophic lateral sclerosis (ALS) and elritercept for cytopenias in myelodysplastic syndromes and myelofibrosis.

The big picture

Keros’ Phase 2 trial for rinvatercept in DMD marks a critical step in expanding treatment options for a disease with high unmet needs. The company’s focus on TGF-β signaling positions it in a competitive biotech landscape where muscle and bone biology modulators are gaining traction. Success in this trial could validate Keros’ platform and attract further investment, but execution risks remain high given the complexity of neuromuscular disorders.

What we're watching

Clinical Progress: The pace at which Keros generates initial data from the Phase 2 trial will signal rinvatercept’s potential in DMD.
Market Differentiation: Whether rinvatercept can demonstrate meaningful functional improvements in both ambulatory and non-ambulatory DMD patients.
Pipeline Strategy: How Keros balances development of rinvatercept for DMD and ALS while advancing elritercept for hematologic disorders.